Abbott Laboratories is optimistic about the prospects for its neuromodulation technology. It cited the potential for quarterly sequential revenue growth increases over 2019 in neuromodulation and has doubled its R&D investment in the field in order to maximize the and expand upon its pair of neuromodulation products.

TEL AVIV, Israel – Generating all kinds of data that can feed artificial intelligence (AI) and machine learning engines is increasingly cheap and, in many ways, easy but interpreting all that data and translating it into information that is useful to users that range from drug developers to patients remains a significant challenge. Addressing this challenge has blurred the boundaries between traditional technology companies and medical technology companies and forced a rethinking of how treatments are provided, and drugs are developed. And the challenge also creates opportunities for companies that can address this gap.